Levofloxacin ophthalmic

Drug Profile

Levofloxacin ophthalmic

Alternative Names: Cravit Ophthalmic; DE-108; Iquix 1.5%; Oftaquix; Quixin

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Santen Pharmaceutical
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Corneal ulcer; Infectious conjunctivitis; Ophthalmic infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Sep 2015 Santen Pharmaceutical initiates enrolment in a phase III trial for Ophthalmic infections in South Korea (NCT02573610)
  • 01 Nov 2012 South Korean Food and Drug Administration declines to approve 1.5% ophthalmic solution of levofloxacin for treatment of Conjunctivitis and other Ophthalmic infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top